Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 88 articles:
HTML format
Text format



Single Articles


    April 2018
  1. BIDARD FC, Michiels S, Riethdorf S, Mueller V, et al
    Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.
    J Natl Cancer Inst. 2018 Apr 12. pii: 4969338. doi: 10.1093.
    PubMed     Text format     Abstract available


  2. CHOI HJ, Joo HS, Won HY, Min KW, et al
    Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  3. VERMA V, Simone CB 2nd, Mishra MV
    Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    March 2018
  4. MATIKAS A, Foukakis T, Bergh J
    RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Mar 29. pii: 4956469. doi: 10.1093.
    PubMed     Text format    


  5. HAWK E, Maresso KC, Brown P
    NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question.
    J Natl Cancer Inst. 2018 Mar 15. pii: 4938606. doi: 10.1093.
    PubMed     Text format    


    February 2018
  6. GAIL MH, Pfeiffer RM
    Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.
    J Natl Cancer Inst. 2018 Feb 27. pii: 4912416. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. ZACHARIAE R, Amidi A, Damholdt MF, Clausen CDR, et al
    Internet-Delivered Cognitive-Behavioral Therapy for Insomnia in Breast Cancer Survivors: A Randomized Controlled Trial.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881759. doi: 10.1093.
    PubMed     Text format     Abstract available


  8. OESTERREICH S, Lucas PC, McAuliffe PF, Bruno TC, et al
    Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881762. doi: 10.1093.
    PubMed     Text format    


  9. DESMEDT C, Salgado R, Fornili M, Pruneri G, et al
    Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881757. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. IRWIN MR
    Innovation in the Treatment of Insomnia in Breast Cancer Survivors.
    J Natl Cancer Inst. 2018 Feb 20. pii: 4881761. doi: 10.1093.
    PubMed     Text format    


  11. BROWN J, Rathbone E, Hinsley S, Gregory W, et al
    Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
    J Natl Cancer Inst. 2018 Feb 7. pii: 4842040. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. HEINDL A, Sestak I, Naidoo K, Cuzick J, et al
    Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  13. TROESTER MA, Sun X, Allott EH, Geradts J, et al
    Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  14. BANDOS H, Melnikow J, Rivera DR, Swain SM, et al
    Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  15. RIVERA DR, Ganz PA, Weyrich MS, Bandos H, et al
    Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  16. JAGSI R, Momoh AO, Qi J, Hamill JB, et al
    Impact of Radiotherapy on Complications and Patient-Reported Outcomes After Breast Reconstruction.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    January 2018
  17. LINDSTROM LS, Yau C, Czene K, Thompson CK, et al
    Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
    J Natl Cancer Inst. 2018 Jan 19. pii: 4780395. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. OZTURK TOPCU T, Jerzak KJ, Warner E
    RE: Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2018 Jan 10. pii: 4797407. doi: 10.1093.
    PubMed     Text format    


  19. LASKY-SU JA, Zeleznik OA, Eliassen AH
    Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795354. doi: 10.1093.
    PubMed     Text format    


  20. MOORE SC, Playdon MC, Sampson JN, Hoover RN, et al
    A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
    J Natl Cancer Inst. 2018 Jan 9. pii: 4795343. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. SCHRIJVER WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, et al
    Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018 Jan 5. pii: 4791841. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. BLOK EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, et al
    Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  23. GOLDVASER H, Barnes TA, Seruga B, Cescon DW, et al
    Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


  24. JOHNSON SB, Park HS, Gross CP, Yu JB, et al
    Use of Alternative Medicine for Cancer and Its Impact on Survival.
    J Natl Cancer Inst. 2018;110.
    PubMed     Text format     Abstract available


    December 2017
  25. POORVU PD, Winer EP
    Adjuvant Chemotherapy for ER+ Breast Cancer: A Sea Change is Underway.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718502. doi: 10.1093.
    PubMed     Text format    


  26. KURIAN AW, Bondarenko I, Jagsi R, Friese CR, et al
    Recent Trends in Chemotherapy Use and Oncologists' Treatment Recommendations for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017 Dec 11. pii: 4718501. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. GLUZ O, Nitz U, Liedtke C, Christgen M, et al
    Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
    J Natl Cancer Inst. 2017 Dec 8. pii: 4698155. doi: 10.1093.
    PubMed     Text format     Abstract available


    November 2017
  28. BELKACEMI Y, Kuten A
    RE: Regional Nodal Irradiation After Breast-Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017 Nov 21. pii: 4645256. doi: 10.1093.
    PubMed     Text format    


  29. MEIER M, Orr N
    Genetic Determinants of Breast Cancer Risk in Childhood Cancer Survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  30. MORTON LM, Sampson JN, Armstrong GT, Chen TH, et al
    Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  31. DESHMUKH AA, Shirvani SM, Lal L, Swint JM, et al
    Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  32. SCHWARZ LJ, Hutchinson KE, Rexer BN, Estrada MV, et al
    An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    October 2017
  33. LAMBERTINI M, Kroman N, Ameye L, Cordoba O, et al
    Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.
    J Natl Cancer Inst. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  34. VISSCHER DW, Frank RD, Carter JM, Vierkant RA, et al
    Breast Cancer Risk and Progressive Histology in Serial Benign Biopsies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available



  35. Restarting Adjuvant Hormone Therapy Improves Breast Cancer Outcomes.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  36. HE W, Smedby KE, Fang F, Olsson H, et al
    Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  37. HERMELINK K, Buhner M, Sckopke P, Neufeld F, et al
    Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  38. ROBSON ME, Reiner AS, Brooks JD, Concannon PJ, et al
    Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    September 2017
  39. BYRNE C, Ursin G, Martin CF, Peck JD, et al
    Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    August 2017
  40. POLLACK CE, Soulos PR, Herrin J, Xu X, et al
    The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  41. SCHMIDT MK, van den Broek AJ, Tollenaar RA, Smit VT, et al
    Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  42. GINGRAS I, Holmes E, De Azambuja E, Nguyen DH, et al
    Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    July 2017
  43. SHAFAEE MN, Ellis MJ
    Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  44. WU X, Ye Y, Barcenas CH, Chow WH, et al
    Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  45. ROJAS PA, May M, Sequeira GR, Elia A, et al
    Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  46. GOETZ MP, Kalari KR, Suman VJ, Moyer AM, et al
    Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  47. KUCHENBAECKER KB, McGuffog L, Barrowdale D, Lee A, et al
    Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    June 2017
  48. SAMANTA SK, Sehrawat A, Kim SH, Hahm ER, et al
    Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  49. DAVE B, Gonzalez DD, Liu ZB, Li X, et al
    Role of RPL39 in Metaplastic Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available



  50. Higher consumption of grilled, barbecued, and smoked meat linked to increased mortality risk among breast cancer survivors.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


    May 2017
  51. KERLIKOWSKE K, Gard CC, Tice JA, Ziv E, et al
    Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  52. WALTER JR, Xu S, Woodruff TK
    A Call for Fertility Preservation Coverage for Breast Cancer Patients: The Cost of Consistency.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


    April 2017
  53. NOLAN E, Vaillant F, Visvader JE, Lindeman GJ, et al
    RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2017 Apr 4. doi: 10.1093.
    PubMed     Text format    


  54. SCHERNHAMMER ES
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  55. HANSEN J
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  56. ERREN TC, Morfeld P, Gross JV
    RE: Night Shiftwork and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  57. STEVENS RG
    RE: Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  58. GARRIDO-CASTRO AC, Winer EP
    Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


    March 2017
  59. MA R, Karthik GM, Lovrot J, Haglund F, et al
    Estrogen Receptor beta as a Therapeutic Target in Breast Cancer Stem Cells.
    J Natl Cancer Inst. 2017;109:1-14.
    PubMed     Text format     Abstract available


    February 2017
  60. ERIKSEN KT, McElroy JA, Harrington JM, Levine KE, et al
    Urinary Cadmium and Breast Cancer: A Prospective Danish Cohort Study.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  61. GREENLEE H, Hershman DL, Shi Z, Kwan ML, et al
    BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  62. BANEGAS MP, John EM, Slattery ML, Gomez SL, et al
    Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  63. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109:2-3.
    PubMed     Text format    


  64. GREENLEE H, Hershman DL, Shi Z, Kwan ML, et al
    BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study.
    J Natl Cancer Inst. 2017;109:1-8.
    PubMed     Text format     Abstract available


  65. ERIKSEN KT, McElroy JA, Harrington JM, Levine KE, et al
    Urinary Cadmium and Breast Cancer: A Prospective Danish Cohort Study.
    J Natl Cancer Inst. 2017;109:1-7.
    PubMed     Text format     Abstract available


  66. SINDZINSKI A
    Risk of Heart Disease in Breast Cancer Patients Receiving Estrogen-Deprivation Therapy.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


    January 2017
  67. PARADA H JR, Steck SE, Bradshaw PT, Engel LS, et al
    Grilled, Barbecued, and Smoked Meat Intake and Survival Following Breast Cancer.
    J Natl Cancer Inst. 2017 Jan 4. pii: djw299. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. KOTSOPOULOS J, Huzarski T, Gronwald J, Singer CF, et al
    Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  69. HILAKIVI-CLARKE L, Warri A, Bouker KB, Zhang X, et al
    Effects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  70. SMITH BD, Jiang J, Shih YC, Giordano SH, et al
    Cost and Complications of Local Therapies for Early-Stage Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  71. PARKES EE, Walker SM, Taggart LE, McCabe N, et al
    Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  72. BENSE RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, et al
    Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.
    J Natl Cancer Inst. 2016;109.
    PubMed     Text format     Abstract available


  73. MAMOUNAS EP, Liu Q, Paik S, Baehner FL, et al
    21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available


  74. HAAS JS
    The Complexity of Achieving the Promise of Precision Breast Cancer Screening.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format    


  75. SHIEH Y, Eklund M, Madlensky L, Sawyer SD, et al
    Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    J Natl Cancer Inst. 2017;109.
    PubMed     Text format     Abstract available



  76. Different Breast Cancer Treatment Options Vary Widely in their Cost-Effectiveness.
    J Natl Cancer Inst. 2017;109:1-2.
    PubMed     Text format    


    December 2016
  77. TRAVIS RC, Balkwill A, Fensom GK, Appleby PN, et al
    Night Shift Work and Breast Cancer Incidence: Three Prospective Studies and Meta-analysis of Published Studies.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available



  78. Night Shift Work and Breast Cancer Risk.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    November 2016
  79. TER BRUGGE P, Kristel P, van der Burg E, Boon U, et al
    Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  80. VISVANATHAN K, Yager JD
    Ethnic Variations in Estrogen and Its Metabolites: Sufficient to Explain Differences in Breast Cancer Incidence Rates?
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    October 2016
  81. MOORE SC, Matthews CE, Ou Shu X, Yu K, et al
    Endogenous Estrogens, Estrogen Metabolites, and Breast Cancer Risk in Postmenopausal Chinese Women.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format     Abstract available


  82. VISVANATHAN K, Yager JD
    Ethnic Variations in Estrogen and Its Metabolites: Sufficient to Explain Differences in Breast Cancer Incidence Rates?
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    August 2016
  83. MARTIN LJ, Huszti E, Connelly PW, Greenberg CV, et al
    RE: Serum Lipids, Lipoproteins, and Risk of Breast Cancer: A Nested Case-Control Study Using Multiple Time Points.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  84. TOOMEY S, Eustace AJ, Pritzker LB, Pritzker KP, et al
    RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  85. SCHMIDT C
    Mammaprint Reveals Who Can Skip Chemotherapy for Breast Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    June 2016
  86. FILLON M
    Continuing To Smoke After Breast Cancer Diagnosis Lowers Survival Rate.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


    April 2016
  87. AZVOLINSKY A
    Unraveling How Obesity Fuels Cancer.
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


  88. JENKS S
    Digital Imaging of the Breast: Is a Synthetic View Better?
    J Natl Cancer Inst. 2016;108.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: